Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells

Erlotinib after Failure of Gefitinib in Patients with Advanced Non-small Cell Lung Cancer Previously Responding to Gefitinib

(2010) Enrico Vasile et al.   Journal of Thoracic Oncology

Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib

(2009) C Lemos et al.   BRITISH JOURNAL OF CANCER

The Role of MET Activation in Determining the Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

(2009) J. K. Rho et al.   MOLECULAR CANCER RESEARCH

First- or Second-line Therapy with Gefitinib Produces Equal Survival in Non–Small Cell Lung Cancer

(2008) Jenn-Yu Wu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment

(2008) D. H. Lee et al.   ANNALS OF ONCOLOGY

Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478

(2008) Zhi Shi et al.   BIOCHEMICAL PHARMACOLOGY

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

(2008) Edward S Kim et al.   LANCET

Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line

(2008) Yukio Nishimura et al.   Molecular Cancer

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice

(2008) S. Marchetti et al.   MOLECULAR CANCER THERAPEUTICS